AG Edwards Cut Vasogen to Hold from Buy

Analyst Kevin McDevitt cites disappointing results from the company's trial of its heart disease treatment technology Celacade

AG Edwards downgraded Vasogen (VSGN) to hold from buy, citing disappointing results from the company's trial of its heart disease treatment technology Celacade.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.